Most recently, it has been determined that conolidine and the above derivatives act over the atypical chemokine receptor 3 (ACKR3. Expressed in similar locations as classical opioid receptors, it binds to some big range of endogenous opioids. Unlike most opioid receptors, this receptor acts like a scavenger and does not activate a second messenger